News

Artery.com's "2018 Future Healthcare 100" list was officially released, and CGeneTech was honored to be listed

  • Categories:Media
  • Author:Arterial network
  • Origin:Arterial network
  • Time of issue:2018-12-20
  • Views:0

(Summary description)On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

Artery.com's "2018 Future Healthcare 100" list was officially released, and CGeneTech was honored to be listed

(Summary description)On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

  • Categories:Media
  • Author:Arterial network
  • Origin:Arterial network
  • Time of issue:2018-12-20
  • Views:0

  On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

 

   On the 18th, Artery.com released the four main lists of "2018 Future Healthcare 100": "China Healthcare Top 100", "China Medicine Top 100", "China Health Top 30" and "Overseas Top 100". The four main lists were "China Health List Top 30" and "Overseas List Top 100". Centurion is fortunate to occupy one of the top 100 China Medical List.


  In addition, Artery.com has added sub-lists (TOP5) in niche areas (rehabilitation robotics, DTP pharmacy, third-party medical services and 12 other areas), as well as "China Top Industrial Park TOP10" and "China Top Industrial New City TOP10" from 2018. ".


  In this era of exploring the future of healthcare, we are looking forward to new technological breakthroughs and innovations, model explorations and improvements that will bring more excitement to the future of human health.


  As an observer and recorder of the industry, we hope to see social change, economic ups and downs and consumer evolution from a Chinese and global perspective, and to discover the direction of change in the health care industry from a broader perspective. "The Future Healthcare 100 aims to select innovative Chinese healthcare companies that truly represent the future of healthcare, discover the core strengths of China's future healthcare industry, and promote the process of innovation and change in the healthcare industry.


  In 2018, the "Future Healthcare 100" list has gone through three stages of production: preliminary selection, review and validation, to explore the most promising companies in various healthcare segments. The list provides a benchmark for innovative companies, a guide for investment institutions and value for audiences.


  The list of companies on the Future Healthcare 100 China 2018 is as follows.

The list of companies on the Future of Healthcare 100 China Medicine list for 2018 is as follows.

 

The list of companies on the Future of Health 100 China Health List 2018 is as follows.

The list of overseas companies in the Future of Healthcare 100 2018 is as follows.

   The 2018 Future Healthcare Industry Report released by Arteries.com - Eggshell Research Institute points out that 2018 was a year of change in the healthcare sector, and China has made a series of achievements in the reform of the sector. The capacity of medical services has been strengthened, the capacity of public health services has been improved, the management of medical institutions has been gradually standardised, the coverage of medical insurance services has been further expanded, the support of regulators for innovative drugs has been stepped up, and medical-related innovative technologies have emerged ......
  These factors have led to the emergence of a number of high-profile companies in various healthcare innovation segments, from traditional companies with a strong commitment to innovation to start-ups that are making the most noise in the healthcare innovation process.
  The "Future Healthcare 100" 2018 annual awards are voted by a panel of judges selected from industry experts, investors and policy researchers, and selected by the Artery Network Content Center, the Eggshell Institute and industry judges, to present the "Future Healthcare 100 The final results include the "Future Healthcare 100" sub-list, the "City New Town" list and the "Park" list.
  The sub-lists include "Rehabilitation Robot", "DTP Pharmacy", "Third Party Medical Services", "Internet of Medical Things", "Pediatric Clinics ", "Paediatric Clinics", "Doctor Groups", "Digital Chinese Medicine", "Digital Equipment for Pharmacies ", "Insurance Payments", "Consumer Genetics", "Gene Editing", "Microbiology " twelve sub-lists, listed below.

2018 Future Healthcare 100 - China List The Industrial Park List/Industrial New City List is as follows.

Source: arterial.com

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO